Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion

Neurosurgery

Volumn 69, Issue 2, 2011, Pages 268-273

  Potts, Matthew B ^a   DeGiacomo, Anthony F ^a   Deragopian, Lenna ^a   Blevins Jr , Lewis S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidiuretic hormone; Arginine vasopressin; Conivaptan; Hyponatremia; SIADH; Vaprisol

Indexed keywords

CONIVAPTAN; CREATININE; SODIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; LOADING DRUG DOSE; MALE; MEDICAL RECORD REVIEW; NEUROSURGERY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL;

ADULT; AGED; BENZAZEPINES; FEMALE; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79960364966     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318218c78f     Document Type: Article

References (10)

1. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064-2072.
2. Sherlock M, O'Sullivan E, Agha A, et al. Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients. Postgrad Med J. 2009;85(1002):171-175.
3. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet. 2008;371(9624):1624-1632.
4. Gross P. Treatment of hyponatremia. Intern Med. 2008;47(10):885-891.
5. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebocontrolled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145-2152.
6. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N; Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27(5):447-457.
7. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: Subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf). 2008;69(1):159-168.
8. Wright WL, Asbury WH, Gilmore JL, Samuels OB. Conivaptan for hyponatremia in the neurocritical care unit. Neurocrit Care. 2009;11(1):6-13.
9. Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009;11(1):14-19.
10. Annane D, Decaux G, Smith N; Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009;337(1):28-36.